In vitro evaluation of temozolomide combined with X-irradiation

Wedge, Stephen R.; Porteous, Julia K.; Glaser, M.G.; Marcus, Kim; Newlands, E. S.

doi:10.1097/00001813-199701000-00013

Cited by 137 publications

(68 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When TMZ is combined with other drugs active against systemic disease, results show a clear amelioration in terms of disease control and survival time [8]. If we consider TMZ as part of a combined treatment with WBRT for patients who have not previously received cranial irradiation, we observed more promising results in quality of life and relief from neurologic symptoms [9,10], confirming the synergistic in vitro data on the combination of TMZ with ionizing radiation [11]. We have recently demonstrated that schedules with protracted low doses of TMZ, such as the continuous 3 weeks on/1 week off regimen in combination with WBRT offer several advantages over conventional therapy [12].…”

supporting

confidence: 62%

The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?

Addeo

Caraglia

2011

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

supporting

confidence: 62%

The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?

Addeo

Caraglia

2011

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

“…In certain cell lines, an enhancement of the radiation effect has been demonstrated, whereas other cell lines have shown no interaction, but merely an additive effect (78)(79)(80)(81)(82)(83).…”

Section: Temozolomidementioning

confidence: 99%

Cell survival and radiosensitisation: Modulation of the linear and quadratic parameters of the LQ model

Franken

Oei

Kok

et al. 2013

International Journal of Oncology

100

View full text Add to dashboard Cite

Abstract.The linear-quadratic model (LQ model) provides a biologically plausible and experimentally established method to quantitatively describe the dose-response to irradiation in terms of clonogenic survival. In the basic LQ formula, the clonogenic surviving fraction S d ̸S 0 following a radiation dose d (Gy) is described by an inverse exponential approximation:, wherein α and β are experimentally derived parameters for the linear and quadratic terms, respectively. Radiation is often combined with other agents to achieve radiosensitisation. In this study, we reviewed radiation enhancement ratios of hyperthermia (HT), halogenated pyrimidines (HPs), various cytostatic drugs and poly(ADP-ribose) polymerase-1 (PARP1) inhibitors expressed in the parameters α and β derived from cell survival curves of various mammalian cell cultures. A significant change in the α/β ratio is of direct clinical interest for the selection of optimal fractionation schedules in radiation oncology, influencing the dose per fraction, dose fractionation and dose rate in combined treatments. The α/β ratio may increase by a mutually independent increase of α or decrease of β. The results demonstrated that the different agents increased the values of both α and β. However, depending on culture conditions, both parameters can also be separately influenced. Moreover, it appeared that radiosensitisation was more effective in radioresistant cell lines than in radiosensitive cell lines. Furthermore, radiosensitisation is also dependent on the cell cycle stage, such as the plateau or exponentially growing phase, as well as on post-treatment plating conditions. The LQ model provides a useful tool in the quantification of the effects of radiosensitising agents. These insights will help optimize fractionation schedules in multimodality treatments.

show abstract

“…It also suggests that introducing chemotherapy early in the disease course is of importance in order to give the drug time to act against this fast-growing tumor. Based on in vitro data, synergy between TMZ and RT is suggested [23][24][25], although the trial design did not allow distinction between the relative contribution of the concomitant treatment part and the maintenance chemotherapy cycles. The outcome of a disease previously considered to be particularly resistant to chemotherapy has been substantially improved with the addition of chemotherapy.…”

Section: Lessons From the Eortc/ncic Randomized Trialmentioning

confidence: 99%

Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma

Stupp

Hegi

Bent³

et al. 2006

The Oncologist

371

241

View full text Add to dashboard Cite

Learning ObjectivesAfter completing this course, the reader will be able to:1. List the different major subtypes of glioma and identify the appropriate treatment strategies for patients with high-grade and low-grade gliomas.2. Discuss the available evidence for the treatment of newly diagnosed glioblastoma, anaplastic astrocytoma, and anaplastic oligodendroglioma.3. Identify approved agents and other active or investigational agents used to treat patients with newly diagnosed and recurrent glioma. shown that early neoadjuvant or adjuvant administration of procarbazine, lomustine, and vincristine chemotherapy prolongs disease-free survival; however, it has no impact on overall survival. Temozolomide, a novel alkylating agent, has shown modest activity against recurrent glioma. In combination with radiotherapy in newly diagnosed patients with glioblastoma, temozolomide significantly prolongs survival. Molecular studies have demonstrated that the benefit is mainly observed Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com CME CME This material is protected by U.S.

show abstract

In vitro evaluation of temozolomide combined with X-irradiation

Cited by 137 publications

References 0 publications

The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?

The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?

Cell survival and radiosensitisation: Modulation of the linear and quadratic parameters of the LQ model

Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma

Contact Info

Product

Resources

About